GSK Frames A Comeback For Its Multiple Myeloma Drug Following Encouraging Phase 3 Data

GSK plc GSK announced headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase 3 trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma. The study included 494 patients previously treated with at least one…#gskplc #gsk #belantamabmafodotin #bordex #00005 #fda #phase3 #dreamm

Source: Reuters: Health - November 27, 2023 Category: Consumer Health News Source Type: news